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Streszczenie
Maciejewski i wsp. [1], w oparciu o przegląd badań klinicznych dotyczących radioterapii chorych na miejscowo zaawansowanego raka 
gruczołu krokowego, doszedł do wniosku, że frakcjonowanie konwencjonalne, tj. frakcje 2 Gy podawane przez 5 dni w tygodniu, może 
prowadzić do tzw. „efektu plateau”. Oznaczałoby to, że podwyższanie całkowitej dawki promieniowania powyżej około 70 Gy nie po-
prawia odsetka wyleczeń miejscowych, lecz może przyczynić się do wzrostu ryzyka późnych odczynów popromiennych. Maciejewski i 
wsp. przedstawili przesłanki przemawiające za tym, by do radykalnej radioterapii chorych na raka gruczołu krokowego wprowadzić hypo-
frakcjonowanie, tj. napromienianie z zastosowaniem wysokich dawek frakcyjnych, posługując się przy tym planowaniem 3 D, modulacją 
intensywności dawki i wybiórczym podwyższaniem dawki w tych częściach guza, które są niedostatecznie utlenowane. W aktualnej pracy 
omówiono natomiast trudności, na które można napotkać próbując wprowadzić te nowe schematy leczenia do praktyki klinicznej. Przed-
stawiono też alternatywny punkt widzenia, dotyczący oceny zależności dawka-efekt w radioterapii chorych na raka gruczołu krokowe-
go: przyjęto bowiem, że gdy miarą niepowodzenia leczenia jest wznowa biochemiczna to „efekt plateau” przy eskalacji dawki może być 
związany z ujawnieniem się przerzutów odległych. Dokonano ponownej analizy danych klinicznych dotyczących związku dawka-efekt w ra-
dioterapii pooperacyjnej. Kontrowersje przedstawione w aktualnej pracy powinny być rozumiane jako bodziec stymulujący do dalszej dys-
kusji dotyczącej optymalizacji leczenia chorych na raka prostaty. Ilustrują one potrzebę badań klinicznych, które pozwoliłyby rozstrzygnąć 
wątpliwości przewidywań opartych o przesłanki teoretyczne.
Słowa kluczowe: rak gruczołu krokowego, zależność dawka-efekt, IMRT, kontrowersje terapeutyczne.
Kontynuacja debaty Maciejewskiego dotyczącej radioterapii chorych 
na zaawansowanego raka gruczołu krokowego: więcej wątpliwości
Summary
A recent critical review of clinical trials on radiotherapy for locally advanced prostate cancer by Maciejewski et al. [1] points to a conclusion 
that most of conventional 5-days-a-week, 2 Gy fraction regimes produce a “plateau effect”. Thus an increase in the total dose above ap-
proximately 70 Gy would not improve local tumour control, but could elevate the risk of later complications. Maciejewski et al. propose that 
radical hypofractionated 3D conformal or dose-intensity modulated radiotherapy with or without 3D HDR boost dose painting may improve 
the outcome of prostate radiotherapy. The present response describes some unforeseen challenges which may appear while implement-
ing these new treatment strategies in clinical practice, and suggests possible solutions to solve these problems. Also, an alternative view-
point on the data on dose-response in radiotherapy for prostate cancer is presented. It is postulated that, in addition to tumour hypoxia, 
distant metastases may create a quasi-plateau in dose-response, when biochemical failures and not loco-regional tumour control are used 
as the endpoint. Some arguments for the presence of dose response in postoperative EBRT for prostate cancer are presented. This some-
what contradictory review of the existing data on radiotherapy for prostate cancer may be considered as a stimulus for further discussion 
regarding optimization of local therapy. It also illustrates an urgent need for new prospective trials, which would address the clinical and ra-
diobiological ambiguities of theoretical predictions.
Key words: dose response, relationship, therapeutic controversies, prostate cancer.
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Study Doses (Gy) Signiﬁcance of dose escalation effect for long-term BNED
Low risk
Pollack et al 2002* [2] 70 vs. 78 NS
Hurvitz et al. 2002# [4] <66.6 vs. 66.6 vs. >66.6 NS
Hanks et al. 1985# [5] <60 vs. 60-70 vs. >70 NS
Pollack et al. 2000# [3] 67-77 vs.>77 NS
Pollack et al. 2000# [3] <67 vs. 67-77 p<0.05
Valicenti et al 1998# [6] <61.5 vs. >61.5 p<0.05
Lyons et al 2000# [7] <72 vs. >72 p<0.05
Intermediate risk
Pollack et al 2002* [2] 70 vs. 78 p<0.05
Pollack et al. 2000# [3] 67-77 vs.>77 p<0.05
Pollack et al. 2000# [3] <67 vs. 67-77 p<0.05
Hanks et al. 1985# [5] <60 vs. 60-70 vs. >70 p<0.05
Valicenti et al 1998# [6] <64.8 vs. >64.8 p<0.05
High risk
Pollack et al 2002* [2] 70 vs. 78 p<0.05
Hanks et al. 1985# [5] <60 vs. 60-70 vs. >70 NS
Valicenti et al 1998# [6] 55.8-70.2 NS
Pollack et al. 2000# [3] 67-77 vs. >77 NS
Pollack et al. 2000# [3] <67 vs. 67-77 p<0.05
Lyons et al 2000# [7] <72 vs. >72 p<0.05
Table 1. The data on the signiﬁcance of dose escalation effect on long-term biochemical failures in prostate cancer. The data are stratiﬁed by risk groups 
for biochemical relapse. Note that the data for low-risk patients consistently show that there is no signiﬁcant dose escalation effect for long-term BNED when 
radiation doses of over 70 Gy were used. By contrast, the data for intermediate risk patients consistently show a signiﬁcant effect from dose escalation 
irrespective of the dose level.
* randomized clinical trial 
# retrospective studies
NS: non significant effect of dose escalation 
p<0.05: statistically significant improvement in BNED from dose escalation
BNED is not a good surrogate for loco-regional tumour 
control, since all distant relapses also result in biochemical 
failure. Therefore the use of BNED for the evaluation of 
the effectiveness of local treatment might have limitations 
which will be outlined below.
 The review of the data on prostate cancer by Maciejewski 
et al. [1] clearly shows that some studies demonstrate 
significant improvement in long-term BNED, while others 
do not. The authors conclude that the compilation of the 
results on BNED for locally advanced prostate cancer 
shows the “plateau effect” for the dose-response above 
70 Gy. A careful examination of Figure 2 from the original 
paper shows, however, that such a conclusion is valid 
mainly for a subset of older studies in which 3-D treatment 
planning has not been used, while flattening of a dose-
response curve restricted to the trials, which utilized 
modern treatment techniques, is less apparent.
 A new perspective can be gained when the published 
data on the dose-response for BNED [2-7] are stratified 
using prognostic factors for biochemical failure such 
Is there evidence of a “plateau effect” for 
dose escalation in conventionally fractionated 
radiotherapy for prostate cancer?
External beam radiotherapy (EBRT) alone
 Following the practice of many other studies Maciejewski 
et al. [1] used long-term Biochemical No Evidence of 
Disease (BNED) as the endpoint for the analysis of 
therapeutic gain from radiation dose escalation in therapy 
for prostate cancer. The practice of using BNED instead 
of loco-regional tumour control has its roots in the biology 
of prostate cancer which regresses slowly, even if locally 
controlled. Thus it is difficult to distinguish a local recurrence 
from a persistent, but sterilized tumour. Furthermore, both 
sensitivity and specificity of PSA monitoring is high in the 
follow-up of prostate cancer making it more cost-effective 
compared to repeated tumour biopsies, bone scintigraphs, 
ultrasonography, CT and MRI imaging. This makes BNED 
a useful tool in determining disease-free survival. However, 
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Figure 1. The proposed shape of radiation dose-response curve for 
biochemical progression free rates in prostate cancer. The data from 4 
studies were used [11-14]. The black dots indicate the average progression 
free rate estimated from 4 studies and the error bars of the reported ranges. 
Note that the curve does not reach 100% even at high radiation doses.
No pts. Adjuvant EBRT(total dose)
The average progression free rate 
(range) Authors
388# 0 Gy (no EBRT) 50%* (40%-64%)
Morgan [11], Stein [12],
Schild [13], Valicenti [14]
137# 55-70 Gy(~60 Gy on the average) 78%* (57%-94%)
Table 2. Summary of the data on adjuvant EBRT for T3N0 prostate cancer compared with prostatectomy alone used by Maciejewski et al [1].
# total number of patients in 4 data sets
*the average value from 4 data sets
as pretreatment PSA concentration, Gleason score and 
tumour stage. This makes possible the review of the 
dose-response data in low, intermediate and high-risk 
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over 70 Gy is, for the most part, restricted to the patients 
with an intermediate risk of relapse and, to a smaller extent, 
to the patients with the highest risk. No benefit from dose 
escalation over 70 Gy is observed in patients with a low 
risk (note that the studies which show some improvement 
with dose escalation in low- risk patients, e.g. [6] used total 
doses of less than 70 Gy). 
 The question thus arises of why the benefit from radiation 
dose escalation over 70 Gy is most evident in patients with 
an intermediate risk of relapse? One should at this point 
appreciate that the incidence of distant metastases in 
prostate cancer is as high as 60% in high-risk tumours, 
and still about 15% in low risk cases [8]. Thus a likely 
explanation for the absence of BNED dose-response effect 
for low risk tumours is that almost all of them are, in fact, 
locally controlled, and the biochemical failures in such 
cases result from metastases to distant organs or to the 
pelvis. By contrast, patients with high-risk tumours may fail 
from metastases irrespectively of whether the tumours are 
locally controlled or not. It is therefore extremely difficult 
to demonstrate the existing, but obscured effect of dose-
response on local tumour control when BNED is used as 
the endpoint. 
 Such an explanation of the outcome of the dose-response 
studies in conventionally fractionated radiotherapy for 
prostate cancer provides an alternative explanation for the 
origin of a plateau in dose-response for biochemical failure. 
One may thus postulate that distant metastases, and not 
hypoxia, are responsible for a plateau in dose-response for 
long-term BNED. Clearly, such a “quasi-plateau” in dose-
response for biochemical failures in prostate cancer differs 
in its origin from the “genuine” plateaus in dose-response 
for local control observed in radiation therapy for head and 
neck cancer, and some other rapidly repopulating tumours 
[9, 10]. 
 Perhaps the most likely explanation of a plateau in dose-
response for prostate cancer is that both tumour hypoxia, 
groups. Although risk criteria were not quite the same in 
each of the published studies, they can be regarded as 
reasonably similar. Table 1 summarizes the data used by 
Maciejewski et al. [1], supplemented by the results from 
the most recent randomized trial performed in the M.D. 
Anderson Cancer Center by Pollack et al. [2], published 
after the submission of the paper by Maciejewski et al. In a 
new trial, 305 patients with prostate cancer were stratified 
by the prognostic factors for biochemical failure, and 
randomized to receive 70 vs. 78 Gy in 2.0 Gy fractions. The 
data collected in Table 1 suggest that the results of this 
new randomized trial are in reasonably good accordance 
with retrospective data from earlier studies [3-7], and show 
that the BNED improvement from radiation dose escalation 
Can hypofractionation for prostate cancer appear 
deleterious?
Is there reliable evidence for low α/β value for 
prostate cancer?
 Recent analysis of the existing data on dose fractionation 
in EBRT and brachytherapy for prostate cancer performed 
by Fowler et al [16] gave the estimate of a very low α/β 
ratio of 1.49 Gy. Such a low α/β value for prostate cancer 
provides theoretical rationale for the use of large doses 
per fraction (hypofractionation) in curative radiotherapy for 
these tumours. 
 Shortly afterwards, however, the data used by Fowler were 
re-analyzed by Nahum et al. [17]. When tumour hypoxia 
and/or high intrinsic radioresistance of subpopulations of 
tumour cells were incorporated into the model, the estimated 
α/β values for prostate cancer were 8.5 Gy and 15.5 Gy 
for well-oxygenated and hypoxic clonogens, respectively. 
This strongly contradicted the results obtained by Fowler, 
and indicated that hypofractionation for prostate cancer 
would have theoretical disadvantage over conventional 
fractionation.
Clinical arguments against hypofractionation for 
prostate cancer
 One of the highlights of the most recent 2003 ASTRO 
meeting was the report from a randomized trial, which 
compared two fractionation schedules for patients with T1 
and T2 prostate cancer [18]. Patients were randomized 
to 66 Gy in 33 fractions over 6.5 weeks (conventional 
arm) vs. 52.5 Gy in 20 fractions of 2.625 over 4 weeks 
(hypofractionation). Both arms were well balanced with 
regard to stage, Gleason score and pretreatment PSA 
level. The total number of patients in the trial was 936. 
There were 460 failures: 216/470 (45.9%) in conventional 
arm vs. 244/466 (52.3%) in hypofractionation, a statistically 
significant difference favouring the conventional arm. The 
acute grade 3 or 4 toxicity was higher in hypofractionation 
(13.5% vs. 8.1%), while grade 3 or 4 late toxicity was similar, 
and low in both arms. 
 The results of the trial are consistent with the hypothesis 
that the α/β value for prostate cancer is likely to be low, even 
though hypofractionation did not improve local control. It 
illustrates that it is difficult to design a hypofractionation 
schedule which would appear superior to conventional 
fractionation in prostate cancer. Also, it does not resolve 
the questioned whether hypofractionation with doses 
higher than 52.5 Gy will appear tolerable. The criticism 
to the design of this study raised at the ASTRO 2003 is 
that the failure rates were high in both trial arms, and that 
currently, the conventionally fractionated dose of 66 Gy 
is considered to be inappropriately low in conventional 
and distant metastases contribute to this effect. Thus the 
observed plateau would have, in fact, two components: a 
“quasi-plateau” in dose-response for BNED resulting from 
distant metastases, and “genuine plateau” in local control 
rates from tumour hypoxia, radioresistance, repopulation, 
and/or geographic errors. 
 Irrespective of the mechanisms of the plateau it is 
important to recognize that intermediate risk tumours 
appear to be the best candidates for dose escalation using 
conventionally fractionated external beam 3-D radiotherapy 
(EBRT). 
 At last, it has to be mentioned after Maciejewski et al [1], 
and after the earlier studies [9,10] that implementation of 
old-fashioned radiation treatment techniques may cause a 
“genuine” plateau to appear in a dose-response for tumour 
control due to systematic or occasional geographical 
misses, dosimetric errors, and inadequate isodose 
distributions. It may also result in unacceptable rates of 
severe normal tissue reactions.
Postoperative EBRT for prostate cancer
 Using the data from the literature [11-14] Maciejewski 
et al concluded that generally, “there is no dose-response 
effect observed for the conventional EBRT given following 
prostatectomy”. Table 2 summarises the data used in that 
paper. It is apparent from these data that increase in total 
radiation dose from 0 Gy (no EBRT) to 55-70 Gy (~60 Gy 
on the average) given in conventional fractions of about 2 
Gy improves biochemical progression free rate from about 
50% to 78%. The data are heterogeneous, and using only 
two data points one can not reliably determine the shape 
of the dose-response curve for biochemical failures in 
postoperative radiotherapy for prostate cancer.  Assuming, 
however, that the dose-response curve for biochemical 
failures resembles the dose-response curves for radiation 
treatment for subclinical cancer [15] one can attempt to plot 
such a curve (Figure 1). The postulated curve is shallow, 
and 20 Gy increment in radiation dose would improve 
progression free rate in postoperative EBRT by only 7%. 
Since the curve is short of reaching 100% even at high 
doses, one may hypothesise that approximately 15%-20% 
of biochemical failures after postoperative radiotherapy 
is due to distant metastases. Also, it would be extremely 
difficult to demonstrate the effect of dose escalation in 
postoperative EBRT for prostate cancer. A randomized trial 
designed to detect 7% improvement in progression free 
rate would have to recruit over 3500 patients to exclude 
the possibility of false negative conclusions. Such a trial 
has not been performed so far, and it is unlikely that it will 
ever be attempted. The lack of level I evidence for dose 
response effect in adjuvant EBRT for prostate cancer can 
not, however, be considered as evidence for the absence 
of the dose response.
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radiotherapy for prostate cancer. Likewise, the total dose 
(52.5 Gy) and the dose per fraction (2.625 Gy) in the 
experimental arm were low, which makes it impossible, to 
fully exploit the theoretical advantage of hypofractionation 
in prostate cancer. Assuming that α/β value for prostate 
is 1.5 Gy the total dose of 52.5 Gy is equivalent to only 
61.9 Gy administered in 2.0 Gy fractions.
 Irrespective of the results of the randomized trial on 
dose fractionation in T1 and T2 tumours one would have 
even greater dilemmas with hypofractionated therapy of 
more advancer, high-risk tumours. This is because cure 
rates in such patients are improved when elective pelvic 
irradiation is used [19]. Is it, thus, rationally justified to use 
hypofractionation for elective pelvic irradiation in prostate 
cancer? Is the low α/β value a unique feature of primary 
prostate cancer, or can analogous feature be attributed 
to pelvic micro-metastases? There is no good answer to 
these questions, and the designers of future clinical trials 
would have to confront serious new dilemmas.
Unforeseen traps of high-tech radiation 
techniques, and the possible solutions
 Numerous studies, including Maciejewski et al. [1], 
discuss the advantages of 3D conformal and IMRT 
therapy for prostate cancer. While the superiority of high-
tech radiation techniques emerges as a new dogma of 
radiotherapy, much less attention is addressed to some 
potential challenges which may appear while implementing 
these new treatments into clinical practice. In this paragraph 
some unforeseen traps of high-tech radiation techniques, 
and the possible solutions will be discussed.
Local tumour control 
 It is too often postulated that technical improvement 
in tumour imaging and dose delivery will quickly be 
transformed into improvement in cure rates of cancer. 
Strict avoidance of normal tissues surrounding the tumour 
is increasingly common in high-tech radiotherapy. Such 
practice raises, however, great concern that even minimal 
inter- or intra- fraction movement of the target organ would 
exclude a part of the tumour from the irradiated volume. 
Also there is reason to be concerned that subclinical 
extensions of the primary cancer and/or metastases will 
be excluded. Thus sparing of the normal tissues would 
be achieved at the expense of tumour control. While the 
mobility of the prostate is relatively low compared to e.g. 
lungs it is obviously not negligible. The topography of 
the pelvis changes considerably during and between the 
fractions of radiotherapy depending on urinary bladder 
continence and large bowel movements. Furthermore, 
there are considerable discrepancies in delineating 
GTV and CTV from one physician to an other and even 
greater diversity between the cancer centres (e.g. lack of 
consensus on indications for irradiation of seminal vessels, 
or prophylactic pelvic irradiation).
 Such a perspective may be quite disturbing bearing 
in mind that only a small number of randomized clinical 
trials have so far been designed to compare control 
rates obtained using conventional 2D vs. “standard” 3D 
radiotherapy, and, to the best of my knowledge, none 
of them has compared local control in “standard” 3D 
conformal RT with IMRT. Excellent isodose distributions on 
the paper may not necessarily convert into improved clinical 
results, because they show physical and not biological 
doses. Furthermore, it has already been pointed out in this 
paper that complete local eradication of the tumour does 
not always result in the cure of cancer. Had the radiation 
oncologist a “supremnac” - a hypothetical therapeutic 
machine, which would allow complete eradication of 
100% of the malignant primary prostate tumours without 
any dose delivered to normal tissue, he would find himself 
in the same position as the surgeon after successful 
prostatectomy. Unfortunately, distant metastases are 
the most common cause of treatment failure in prostate 
cancer in spite of early detection. Since effective adjuvant 
hormonal therapies for prostate cancer exist, combination 
of high-tech radiotherapy and hormonal treatment offer a 
solution of this obvious problem.
 A reasonable solution to the difficulties associated with 
topographical location of a tumour, delineation of GTV, 
and/or micrometastases, in spite of access to high-tech 
diagnostics equipment, is the use elective irradiation. 
This is because the doses, which are used to control 
subclinical cancer, not only contribute to the reduction in 
subclinical metastases, but also provide a “safety margin” 
for uncertainties in the delineation of a primary tumour. 
Remarkably, a dose to sterilize clonogens in a minute 
portion of a primary cancer, which would remain beyond 
high-dose volume, is much lower than the dose to sterilize 
a whole tumour. This is because the number of clonogens 
in the microscopic portion of a tumour is much smaller than 
that in a gross tumour. The results of a recent clinical trial 
on a whole-pelvis versus prostate-only radiotherapy [19] 
shows a clear benefit of elective pelvic irradiation in high-
risk prostate patients. The question of whether elective field 
or shrinking-field technique is justified in low-risk patients 
remains to be solved in future trials. 
Subclinical disease 
 One of the potential traps of IMRT is the ability to 
construct non-homogeneous dose-distribution inside the 
PTV (planning target volume) so that GTV (a tumour) is 
treated with a higher dose per fraction, and a higher total 
dose than CTV (subclinical disease). Such technique would 
allow delivery of e.g. 76 Gy given in 38 fractions of 2.0 Gy 
in the overall treatment time of 53 days to the primary 
tumour, while subclinical cancer (the electively treated part 
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Figure 2. The model cell survival-curves which incorporate the effect of 
hypersensitivity of normal tissues to low doses per fraction. 
a) an initial portion of cell-survival curve shows that within the range of 
doses per fraction of about 0.1-1.0 Gy there is much more cell kill than that 
predicted from a linear-quadratic model,
b) at higher doses per fraction the shape of the cell-survival curve is 
analogous to that predicted by a linear-quadratic model.
rate of a subclinical tumour deposits may be much faster 
than that of a primary cancer. Another problem previously 
discussed of low doses per fraction in prostate cancer is 
its unusual radiobiological characteristics with respect to 
the fraction size. Assuming that α/β for prostate cancer is 
1.5 Gy, 50 Gy given in 38 fractions would be biologically 
equivalent to only 40.2 Gy given in 2.0 Gy fractions.
 It can thus be postulated that unnecessary protraction 
of the overall treatment time in elective pelvic irradiation 
for prostate cancer should be avoided. Perhaps future 
developments in molecular biology and imaging will allow 
the identification of individuals who may actually benefit 
from treatment protraction. 
Late responding tissues
 A troublesome dogma regarding 3-D conformal 
radiotherapy and IMRT is that such techniques will 
decrease the rate of normal tissue complications because 
the total dose and doses per fraction given to such tissues 
are low. This can be achieved by using multiple beams, 
which would almost-perfectly focus on the target volume. 
This conclusion apparently ignores growing evidence of 
hypersensitivity of normal tissues to low doses per fraction. 
Several pre-clinical studies show that there is little, if any, 
DNA repair if fraction doses of about 0.3-0.6 Gy are used 
[20]. A likely explanation of such unexpected phenomenon 
is that low doses per fraction are not high enough to trigger 
molecular mechanisms of repair (Figure 2). Unfortunately, 
large volumes of normal tissues are often exposed to low 
doses per fraction when multiple beams are used (Figure 
3a). The double trouble is that low radiation doses have a 
known potential for induction of a second cancer, and that 
the relationship between the risk of such induction and the 
total dose is non-linear with a highest risk for leukemia at 
about 1.0 Gy. 
 How high would be a dose given in 0.5 Gy per fraction 
to risk necrosis of subcutaneous tissues? Assuming that 
no repair occurs at such fraction doses the total dose to 
induce severe late effect would have to be similar to the 
doses which are historically known to cause necrosis with 
a single dose irradiation, i.e. about 24-26 Gy. Considering 
a situation described in Figure 3 80 Gy given to the tumour 
would result in the accumulation of 20 Gy in 0.5 Gy per 
fraction in large volumes of normal tissues. Luckily, this is 
much less than the hypothetical dose-threshold for severe 
late complications in the absence of DNA repair. However, 
if the total radiation dose for the tumour were escalated to 
100 Gy the dose accumulated in 0.5 Gy per fractions would 
be 25 Gy. This may result in unexpected problems.
 The postulated solution of the problems associated with 
low-dose hypersensitivity and risk of a second cancer is 
avoidance of low radiation doses distributed over large 
volumes of normal tissues. This can easily be avoided when 
the number of beams is reasonably reduced (Figure 3b). 
of the pelvis) would be irradiated in the same overall 
treatment time to the total dose of 50 Gy. Thus the electively 
treated volume would be treated with 1.32 Gy/fraction, 
i.e. the average rate of dose accumulation in the pelvis 
would be 6.6 Gy/week. The advocates of such intensity 
modulated technique believe that a low dose per fraction in 
the pelvis would decrease the rate of acute and late normal 
tissue reactions without compromising local control in the 
pelvis. This could be predicted since prostate cancer is 
on average a slowly growing tumour, and there would be 
little, if any, repopulation during 7-8 weeks of the therapy. 
The problem however is, that the estimates of Tpot for a 
considerable proportion of prostate tumours indicate that 
they may repopulate rapidly. Furthermore, virtually nothing 
is known about repopulation of micrometastases in the 
pelvis, because all of the available data on repopulation and 
dose-time effect in radiotherapy for prostate cancer come 
from the data on primary cancer. However, the existing data 
on other types of cancer suggest that the repopulation 
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Figure 3. Suppose that a dose per fraction prescribed to GTV is 2.0 Gy 
and that 8 beams are used. The weights of the beams are equal, that is 
0.25 Gy is given from each beam. Since there are 4 pairs of the opposed 
beams large volumes of normal pelvic tissue surrounding the tumour will be 
irradiated with about 0.5 Gy per fraction (Figure 3A). Much smaller volumes 
of normal tissues are irradiated with low doses when only 3 beams are 
used, but critical organs may receive a higher total dose (Figure 3B). It is 
not easy to resolve which treatment plan is better if the phenomenon of 
hypersensitivity of low doses to radiation is taken into account. 
Colours (dose per fraction): red: 2.0 Gy, yellow:1.9-2.0 Gy, purple:1.5-1.9 
Gy, green: 0.6-1.5 Gy, blue: 0.2-0.6 Gy
implementation of IMRT.
 The trouble is that unconventional fractionation schemes, 
which have the potential for sparing of normal tissue 
(e.g. CHART), are, theoretically at least, inappropriate for 
prostate cancer because of their unique characteristics 
with respect to fractionation sensitivity (postulated low 
α/β value). Radio-protectors have the theoretical potential 
for sparing normal tissue, but their clinical feasibility is 
still the subject of critical discussion, and they have, so 
far, a lofty prices. This shows that high-tech radiotherapy 
will, most likely, play a major role in routine treatments for 
prostate cancer. One should, however, bear in mind the 
limitations and traps of this technique when trying ensure 
the appropriate use of this new tool.
Can hypoxia by be overcome by “dose painting” 
to become useful in the clinic?
 If hypoxic spots exist in a tumour how high should the 
dose be to sterilize the hypoxic clonogens in such a place? 
Suppose that SF2Gy for well oxygenated prostate cancer 
cells is 0.55, and that an early stage tumour contains 108 
clonogens, than a Poison model of tumour control would 
predict 65 Gy as the dose to achieve 80% probability 
of tumour control, which is reasonably-well consistent 
with clinical data. If, however all clonogens in a tumour 
containing 108 cells were hypoxic, the dose to achieve 
80% probability of hypoxic tumour would be 3x65=195 Gy, 
because the oxygen enhancement ratio for most of human 
cells is about 3.0. If, by contrast, only 104 clonogens were in 
a hypoxic spot than the dose to control such a spot would 
be 97.5 Gy (i.e. 50% of the dose to control 108 cells), and 
146 Gy for a spot containing 106 hypoxic clonogens (i.e 
75% of the dose to control 108 cells). 
 Is it technically possible to deliver such a dose to hypoxic 
spots without risking severe overdosing of normal tissues 
in the proximity of the tumour? With high-tech brachyterapy 
it seems likely that such doses may be safely achieved in 
the near future. However, the question arises of whether 
the use of hypoxic cell sensitizers would better do the task 
than “dose-painted” radiation therapy alone, or whether 
tumours containing hypoxic spots are, perhaps, the best 
candidates for surgery. Does re-oxygenation play a role in 
fractionated radiotherapy for prostate cancer? Only future 
trials can solve these questions.
Summary
 The present review challenges the viewpoint presented 
by Maciejewski et al. that conventional 5-days-a-week, 
2 Gy fraction regimes produce a “plateau effect” in 
therapy for prostate cancer, and that an increase in the 
total dose above 70 Gy would not improve local tumour 
control in this tumour site. It is suggested that not only 
tumour hypoxia, but also distant metastases may create 
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In each individual case the potential gain from the reduction 
of the beam number must be, however, carefully weighed 
against the risk of overdosing critical organs. 
IMRT vs. fractionation vs. radio-protectors in 
prostate cancer 
 Some grumpy people translate the acronym “IMRT” as 
“I�M Really Tired”, because they think there is too much 
work to do. It is because this procedure is considerably 
more time-consuming than the does it “standard” 3-D 
radiotherapy. Not only take longer to prepare a treatment 
plan, but it takes much more time on the treatment machine 
to deliver a defined radiation dose to the target in a dynamic 
way. Also, in-vivo dosimetric procedures are far more 
complicated in IMRT than in “standard” 3-D radiotherapy. 
It is not possible to double-check the calculations using 
standard treatment planning units. It is postulated that 
using unconventional fractionation schedules and/or 
radio-protectors of normal tissues, it may be possible to 
get a similar sparing effect for normal tissues as from the 
Oncol. 1997;15:3214-22.
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geneity in tumor cell kinetics on radiation dose-response. 
An exploratory investigation of a plateau effect. Radiother 
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GG. Prostate specific antigen values after radical retrop-
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Urol.1991;145:319-23.
12 Stein A, de Kernion JB, Dorey F, Smith RB. Adjuvant radio-
therapy in patients post-radical prostatectomy with tumour 
extending through capsule or positive seminal resides. 
Urol. 1992;39:59-62.
13. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, 
Frick LM, et al. Radiotherapy for isolated increases in se-
rum prostate-specyfic antigen levels after radical prostate-
ctomy. Mayo Clin Proc. 1994;69:613-19.
14. Valicenti RK, Gomella LG, Perez CA. Radiation therapy af-
ter radical prostatectomy: a review of the issues and op-
tions. Semin Radiat Oncol. 2003;13:130-40.
15.  Withers HR, Peters LJ, Taylor JMG. Dose-response rela-
tionship for radiation therapy of subclinical disease. Int J 
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tate tumours really low? Int J Radiat Oncol Biol Phys. 
2001;50:1021-31.
17.  Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman 
JD. Incorporating clinical measurements of hypoxia into 
tumor local control modeling of prostate cancer: implica-
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tion schedules for patients with localized prostate cancer. 
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duced radioresistance. Mutation Research 1996;358:171-
183.
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a quasi-plateau in dose-response for prostate cancer, 
when biochemical failures and not loco-regional tumour 
control are used as the endpoint. A conclusion that 
intermediate-risk prostate cancers are good candidates for 
dose escalation in conventionally fractionated radiotherapy 
is presented. Also, some unforeseen challenges, 
which may appear while implementing new radiation 
treatment strategies in the treatment for prostate cancer, 
are discussed, and possible solutions to solve these 
problems are proposed. Furthermore, some arguments 
are given against hypofractionation for prostate cancer. 
Such openly controversial opinions are aimed to stimulate 
a broader discussion regarding the optimization of local 
therapies for prostate cancer. The conclusions presented 
illustrate an urgent need for new prospective trials, which 
would address clinical and radiobiological ambiguities of 
theoretical predictions.
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